AN UNBIASED VIEW OF MOLNUPIRAVIR

Pharmacological inhibition of the ataxia telangiectasia and Rad3-similar protein serine/threonine kinase (ATR; often called FRAP-similar protein (FRP1)) has emerged for a promising technique for cancer therapy that exploits synthetic lethal interactions with proteins linked to DNA injury repair, overcomes resistance to other therapies and improves